米托蒽醌联合足叶乙甙为主方案治疗难治性恶性血液病的临床观察  

Mitoxantrone combined with etoposide in the treatment of refractory leukemia

作　　者：高力[1] 张曦[1] 陈幸华[1] 刘林[1] 孔佩艳[1] 刘红[1] 王庆余[1] 

机构地区：[1]第三军医大学新桥医院血液科,重庆400037

出　　处：《重庆医学》2005年第9期1324-1325,共2页Chongqing medicine

摘　　要：目的评价米托蒽醌和足叶乙甙为主的联合化疗方案治疗难治性急性白血病26例、难治性非霍奇金淋巴瘤20例(NHL)的疗效和不良反应.方法急性非淋巴细胞白血病采用ME方案: MIT 10mg/m2×3d, VP-16 100mg/m2×3～5d;急性淋巴细胞白血病、恶性淋巴瘤采用MOEP方案: MIT 10mg/m2×3d, VP-16 100mg/m2×3～5d, VCR 2mg/m2第1天, Pred 60～80mg/m2×7d;每4周重复,化疗2～3次.结果白血病患者1疗程总有效率为84.6%(CR率为53.8%,PR率30.8%),NHL患者1疗程总有效率90%(CR率75%,PR率15%).主要不良反应为骨髓抑制,白细胞和血小板分别在化疗后第4～9天、第5～14天降到最低值,外周血象一般在 11～15d恢复正常.其余不良反应不明显,无1例患者因化疗不良反应死亡.结论米托蒽醌和足叶乙甙为主的联合化疗方案是治疗难治性白血病/恶性淋巴瘤的较理想方案.Objective To evaluate the effects and toxicities of a regimen of therapy using mitoxantrone （MIT） combined with etoposide （VP-16） for 26 patients with refractory acute leukemia and 20 patients with refractory non-Hodgkin lymphoma. Methods The patients with ANLL were treated with MIT 10mg/m^2×3d, VP-16 100mg/m^2×3-5d;the patients with ALL or NHL were treated with MIT 10mg/m^2 × 3d, VP-16 100mg/m^2 × 3-5d, VCR 2mg/m^2 d1, Pred 60-80mg/m^2×7d. The regiments were repeated every 4 weeks and every patients had gotten 2-3cycles treatment. Results After one period treatment using the ME regimen ,total effective rate respectively is 84. 6% （CR 53.8% ,PR 30.8%） in leukemic patients and 90%（ CR 75% ,PR 15%） in patients with NHL. The chief adverse side effect of ME was severe and sustaining bone marrow suppression. The counts of the leukocyte and thrombotocyte respectively fell to the lowest after treatment 4-9d and 5-14d. It took 11-15d recovery. The other adverse side effects were not obvious and no patients died or stopped the treatment because of the adverse side effects. Conclusion ME regimen can achieve the perfect results in patients with refractory AL/ML.

关 键 词：难治性恶性血液病 米托蒽醌 足叶乙甙 

分 类 号：R733[医药卫生—肿瘤]